Standard BioTools Inc. Non Peo Neo Avg Total Comp Amt
Standard BioTools Inc. (LAB) reported Non Peo Neo Avg Total Comp Amt of $2.85 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-27.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-27
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $2.85M DEF 14A · filed 2026-04-27 |
| 2024-12-31 | $2.72M DEF 14A · filed 2026-04-27 |
| 2023-12-31 | $1.23M DEF 14A · filed 2026-04-27 |
| 2022-12-31 | $3.63M DEF 14A · filed 2026-04-27 |
| 2021-12-31 | $2.15M DEF 14A · filed 2026-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |